Home > Cardiology > Multivessel PCI gaining favor as STEMI therapy

Multivessel PCI gaining favor as STEMI therapy


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
JAMA Cardiology
Reuters Health - 12/11/2020 - Institutional adoption patterns are mixed, but multivessel (MV) percutaneous coronary intervention (PCI) is gaining ground over the guideline-recommended and leading treatment of ST-elevation myocardial infarction (STEMI), culprit-only PCI, according to a nationwide analysis. As Dr. Eric A. Secemsky told Reuters Health by email, "We found substantial temporal variation in use of multivessel PCI among patients with multivessel coronary disease and STEMI, which coincided with emerging evidence. At the end of our study, MV PCI was on the rise, but still pursued in the minority of STEMI patients." "In the context of the positive COMPLETE trial," he added, "the largest trial to date that demonstrated a clinical benefit with complete revascularization of all diseased vessels, we anticipate a large change in clinical care as these results are adopted into routine practice." To determine the impact of these findings, Dr. Secemsky of Harv...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on